Karim, N.A.; Ullah, A.; Pathrose, P.; Fathallah, H.; Perry, A.; Morris, J.C.; Wang, J.; Starnes, S.L.
Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning? Curr. Oncol. 2022, 29, 4779-4790.
https://doi.org/10.3390/curroncol29070379
AMA Style
Karim NA, Ullah A, Pathrose P, Fathallah H, Perry A, Morris JC, Wang J, Starnes SL.
Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning? Current Oncology. 2022; 29(7):4779-4790.
https://doi.org/10.3390/curroncol29070379
Chicago/Turabian Style
Karim, Nagla Abdel, Asad Ullah, Peterson Pathrose, Hassana Fathallah, Ashley Perry, John C. Morris, Jiang Wang, and Sandra L. Starnes.
2022. "Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?" Current Oncology 29, no. 7: 4779-4790.
https://doi.org/10.3390/curroncol29070379
APA Style
Karim, N. A., Ullah, A., Pathrose, P., Fathallah, H., Perry, A., Morris, J. C., Wang, J., & Starnes, S. L.
(2022). Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning? Current Oncology, 29(7), 4779-4790.
https://doi.org/10.3390/curroncol29070379